A Phase 3 interventional study of Semaglutide 2.4mg and Placebo in Obesity, Obesity; Drug and Overweight or Obesity, sponsored by Loma Linda University. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Loma Linda University · Phase 3, Interventional, and Treatment
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's enrollment of 119 is above the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Loma Linda University is the lead sponsor of 305 studies on the registry; 48 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 23 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Will receive active medication semaglutide subcutaneously, once weekly, self-injection. Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7)
Drug: Semaglutide 2.4mg
Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.
Drug: Placebo
The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
A placebo will be given to the control group per the schedule outlined in the armed description.
Assessment of weight loss.
Assessment will be based on pounds lost between baseline and final study visit.
Time frame: Change between baseline and final study visit, seven months post baseline.
Food Addiction Assessment
Yale Food Addiction Scale Survey administered to subjects at baseline and month four of treatment. Assessment results based on multiple survey questions regarding intake of specific food types (sugar, starch, sweet, salty, savory).
Time frame: Change between baseline and month four of treatment.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide